Ranitidine, sold for decades under the brand name Zantac, was one of the most commonly prescribed acid-reducing medications for children with gastroesophageal reflux disease (GERD). That changed in 2020 when the FDA requested that all ranitidine products be pulled from the market after testing revealed the drug could form unacceptable levels of a probable carcinogen called NDMA. Today, ranitidine is no longer available in any form, including pediatric formulations. But the story of Zantac and kids involves more than the recall: even before the drug disappeared, a growing body of research was raising questions about whether acid-suppressing medications were being prescribed too freely to infants and young children.
When Reflux in Children Actually Needs Treatment
Most babies spit up, and most of the time that spitting up is harmless. Gastroesophageal reflux in infants is a normal physiological event that happens several times a day, usually after feeding, and causes no real problems. These babies are sometimes called “happy spitters” because they gain weight normally and are otherwise comfortable.1PubMed. Gastroesophageal reflux disease in neonates and infants: when and how to treat Most outgrow it by their first birthday without any medication at all.
The situation is different when reflux leads to complications. GERD is the diagnosis when stomach contents coming back up cause symptoms that affect a child’s quality of life or lead to problems like poor weight gain, feeding difficulties, chronic respiratory issues, inflammation of the esophagus, or blood in vomit.2PubMed. Gastroesophageal reflux disease in neonates and infants: when and how to treat An international consensus group has emphasized that infant reflux is mostly benign and only warrants the GERD label when associated with complications such as failure to thrive.3PubMed. Infant gastroesophageal reflux disease management consensus The distinction matters because it determines whether any medication is justified in the first place.
How Ranitidine Worked in Children
Ranitidine belonged to a class of drugs called H2 receptor antagonists, or H2 blockers. These drugs reduce stomach acid by blocking specific receptors on the acid-producing cells in the stomach lining.4PubMed Central. Clinical use of gastric antisecretory drugs in pediatric patients with gastroesophageal reflux disease: a narrative review The result is less acid in the stomach and, in theory, less irritation when stomach contents wash back into the esophagus.
In children, ranitidine was absorbed fairly quickly after an oral dose, reaching peak blood levels within a couple of hours. Its elimination half-life in both infants and older children hovered around two to three hours, meaning the drug cleared the body relatively fast and typically needed to be given more than once a day.5Journal of Pharmacology and Clinical Toxicology. Clinical Pharmacology of Ranitidine in Infants and Children One consistent finding across pediatric studies was wide variation from child to child in how the drug was processed, which made dosing less predictable than clinicians would have liked.6PubMed Central. Pharmacokinetics of ranitidine in preterm and term neonates with gastroesophageal reflux Preterm infants, for instance, tended to have higher drug levels than full-term babies given the same weight-adjusted dose.
Even when the drug was still on the market, H2 blockers like ranitidine were considered less effective than proton pump inhibitors (PPIs) at relieving GERD symptoms and healing esophagitis in older children and adolescents.7PubMed Central. Clinical use of gastric antisecretory drugs in pediatric patients with gastroesophageal reflux disease: a narrative review In infants specifically, the evidence for benefit was surprisingly thin. A withdrawal study comparing the H2 blocker famotidine (a close relative of ranitidine) to placebo in infants with clinically diagnosed GERD found no meaningful difference in crying, regurgitation frequency, or growth between the drug and placebo groups.8Arquivos de Gastroenterologia. Antisecretory treatment for pediatric gastroesophageal reflux disease – a systematic review That finding reflected a broader pattern: many fussy, spitting-up babies placed on acid blockers had ordinary reflux, not true GERD, and the medication was unlikely to help.
Why Ranitidine Disappeared From the Market
In 2019, independent laboratories detected NDMA (N-Nitrosodimethylamine) in ranitidine tablets. NDMA is classified as a probable human carcinogen, and its presence in a widely used medication set off alarm. Testing showed that the NDMA problem was not limited to contamination during manufacturing; ranitidine’s own chemical structure could generate NDMA over time, especially when stored at higher temperatures. By April 2020, the FDA asked all manufacturers to withdraw ranitidine products from the market. The decision applied to both prescription and over-the-counter versions, including pediatric formulations.
GSK, the original maker of Zantac, later agreed to pay up to $2.2 billion to resolve the majority of US state court lawsuits alleging the drug caused cancer, covering roughly 80,000 plaintiffs across multiple jurisdictions, though the company admitted no liability.9BMJ. GSK settles most US lawsuits over Zantac for $2.2bn The scale of that settlement underscored how widely ranitidine had been used for decades before the contamination issue came to light.
Infection Risk From Suppressing Stomach Acid in Children
Stomach acid does more than digest food. It acts as a chemical barrier against bacteria and other pathogens that enter through the mouth. When you suppress that acid in a child, the barrier weakens, and certain infections become more likely. This concern applied to ranitidine and applies equally to any acid-suppressing drug still in use.
A large systematic review and meta-analysis found that both H2 blockers and PPIs were associated with an increased risk of community-acquired and hospital-acquired pneumonia.10PubMed Central. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis In children specifically, a study comparing kids on acid-suppressing medications to healthy controls found significantly higher rates of both acute gastroenteritis and community-acquired pneumonia during four months of follow-up. The same study also found that infection rates within the treated group were higher in the months after starting medication compared to the months before.11Pediatrics. Therapy With Gastric Acidity Inhibitors Increases the Risk of Acute Gastroenteritis and Community-Acquired Pneumonia in Children
The risk appears even more concerning for vulnerable populations. A review of ten years of literature on adverse effects of GERD medications in children concluded that acid suppression may place immune-deficient infants and children, or those with indwelling catheters, at particular risk for lower respiratory tract infections and hospital-acquired bloodstream infections.12PubMed Central. Adverse effects reported in the use of gastroesophageal reflux disease treatments in children: a 10 years literature review For a premature infant in a neonatal intensive care unit, those are not minor concerns.
The Allergy Connection
One of the more unexpected findings in pediatric acid suppression research is a link between early use of these drugs and later development of food allergies. The mechanism that researchers suspect is straightforward in concept: stomach acid helps break down food proteins before they reach the immune system. Suppress the acid, and more intact food proteins arrive in the gut, where an immature immune system may mistakenly flag them as threats.
A study using a large US insurance database found that children with GERD who were treated with acid-suppressing medications had roughly 1.7 times the risk of developing at least one food allergy within a year compared to children with GERD who received no medication.13PubMed Central. Development of food allergies in patients with Gastroesophageal Reflux Disease treated with gastric acid suppressive medications A separate large study of over 790,000 children looked specifically at H2 blockers and PPIs prescribed during infancy and found substantially elevated risks of food allergy with both drug classes. Cow’s milk allergy showed the steepest increase.14JAMA Pediatrics. Association Between Use of Acid-Suppressive Medications and Antibiotics During Infancy and Allergic Diseases in Early Childhood
More recent research has reinforced the pattern. A 2024 study found that H2 blocker exposure in infancy was associated with a fourfold increase in food allergy risk and a higher risk of anaphylaxis. Even when the analysis was restricted to infants who had a confirmed GERD diagnosis, the association between acid-suppressive medication and food allergy persisted, with risk ratios remaining elevated for both PPIs and H2 blockers.15PubMed Central. Association of Acid-Suppressive Medication and Antimicrobial Use in Infancy with Food Allergy and Anaphylaxis These are observational studies, so they cannot prove that the drugs directly caused the allergies. But the consistency of the association across multiple large datasets, and the biological plausibility of the mechanism, has made pediatric gastroenterologists increasingly cautious about prescribing acid suppressors to young infants.
Bone Fracture Risk in Young Children
Acid-suppressing drugs can interfere with calcium absorption, which has prompted researchers to investigate whether children on these medications break bones more often. The picture is somewhat reassuring for H2 blockers specifically: a meta-analysis of observational studies found that H2 blocker use alone was not significantly associated with fracture risk in children or young adults.16PubMed. Use of acid-suppressive drugs and risk of fracture in children and young adults: a meta-analysis of observational studies
PPIs, however, tell a different story. After adjusting for other factors, PPI use in early childhood was associated with a roughly 21% increase in fracture risk, and children who received both PPIs and H2 blockers saw an even higher increase of about 30%.17Pediatrics. Early Acid Suppression Therapy Exposure and Fracture in Young Children The risk was greatest in children who started acid-suppressive medication before six months of age, and it rose with longer treatment duration. For parents whose children are currently on a PPI, the practical takeaway is that shorter courses at the lowest effective dose are preferable to indefinite use.
Effects on the Developing Gut Microbiome
A baby’s gut microbiome is still being assembled during the first year or two of life, and what happens during that window can have lasting effects. Acid-suppressing drugs alter the chemical environment of the gut, and researchers have started documenting what that means for the microbial communities developing there.
Studies looking at infants on H2 blockers like ranitidine found that treatment decreased gut microbial diversity and shifted the balance of bacterial communities, with increases in certain potentially harmful groups and decreases in beneficial ones.18eClinicalMedicine. Exposure to prescribed medication in early life and impacts on gut microbiota and disease development Infants with reflux who were exposed to PPIs also showed altered gut microbiota, and longer duration of PPI use was associated with greater changes in microbial diversity and composition.19PubMed Central. Effect of proton pump inhibitors in infants with esophageal atresia on the gut microbiome: a pilot cohort A study comparing infants with reflux to healthy controls found consistently elevated microbial diversity in the reflux group, with the most pronounced differences in infants who had been on PPIs for more than 30 days.20PubMed Central. Gastroesophageal reflux and PPI exposure alter gut microbiota in very young infants
This research is still in its early stages, and the long-term health consequences of these microbial shifts are not yet clear. But disruptions to the infant gut microbiome have been linked in other research to immune system development, and it is plausible that drug-induced microbial changes contribute to the allergy associations described above. At minimum, the findings add another reason to avoid prescribing acid suppressors to infants who do not truly need them.
What Replaced Ranitidine
After the ranitidine recall, clinicians shifted to other options. Famotidine, another H2 blocker that does not share ranitidine’s NDMA problem, became the default substitute for situations where an H2 blocker was considered appropriate. PPIs like omeprazole and esomeprazole remained available for more severe GERD. A Cochrane systematic review comparing omeprazole to ranitidine in infants found that both drugs produced similar improvements in symptom scores, with very low certainty about whether one was meaningfully better than the other.21Cochrane Database of Systematic Reviews. Pharmacological treatments for gastro-oesophageal reflux in infants and children
For infants, though, the first-line approach increasingly emphasizes non-drug measures. Thickened feeds, upright positioning after meals, and smaller, more frequent feedings are recommended before any medication is tried. In some cases, the apparent reflux symptoms are actually caused by cow’s milk protein allergy rather than acid. One small trial found that switching infants to a hypoallergenic formula reduced vomiting just as effectively as ranitidine, with both approaches producing improvement in about three-quarters of babies.22Innovative Journal of Pediatrics. Comparison of Hypoallergenic Diet vs. Ranitidine in Treatment of Gastroesophageal Reflux Disease of Infants: A Randomized Clinical Trial That result highlights how often the underlying problem may not be acid at all.
What Current Guidelines Recommend
Joint clinical practice guidelines from the two major pediatric gastroenterology societies (NASPGHAN and ESPGHAN) recommend against using a trial of PPIs as a diagnostic test for GERD in infants. In older children who can describe symptoms like heartburn or chest pain, a four-to-eight-week trial of a PPI is considered a reasonable diagnostic step. But for babies who cannot report their own symptoms, the guidelines are clear that prescribing acid suppressors to see if they help is not appropriate practice.23PubMed Central. Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN)
Despite these guidelines, overprescription of acid-suppressing medications to infants remains a well-documented problem. The gap between the evidence and clinical practice is driven by several factors: parents understandably want something to help a crying, spitting-up baby, and it can feel dismissive for a doctor to say “wait it out.” Prescribing a medication signals that the concern is being taken seriously. But the accumulating evidence on infection risk, allergy development, and microbiome disruption has made the case for restraint harder to ignore.
Excipient Concerns in Pediatric Liquid Formulations
One issue that rarely comes up in conversations between doctors and parents involves the inactive ingredients in pediatric liquid medications. Oral syrups and solutions formulated for infants and young children sometimes contain excipients like ethanol, propylene glycol, or benzyl alcohol. A review of international literature found that several medicines commonly given to newborns contain potentially harmful excipients, and urged clinicians to be aware of the issue when choosing formulations.24Journal of Pediatric and Neonatal Individualized Medicine. Neonates exposed to excipients: concern about safety This applies broadly to pediatric medicines, not just acid blockers, but it is worth noting because liquid ranitidine formulations were among the drugs commonly given to very young infants. When any medication is prescribed for a newborn or premature baby, asking about the inactive ingredients in the specific formulation is reasonable.
Iron Absorption and Long-Term Acid Suppression
Stomach acid plays a role in converting dietary iron into a form the body can absorb. When acid levels are chronically suppressed, iron absorption can suffer. A detailed review with long-term case follow-up documented iron deficiency anemia developing in patients on combinations of PPIs, H2 blockers, and calcium carbonate over extended periods, though the authors noted that overt iron deficiency anemia from acid-modifying medications alone is likely uncommon in people without other risk factors for iron deficiency. For children already at risk of low iron, such as premature infants, picky eaters, or those on restricted diets, prolonged acid suppression adds another variable that clinicians should monitor.